A Phase 1 Study of KIN-3248, an irreversible small molecule pan-FGFR inhibitor, in Patients with Advanced FGFR 2/3 Driven Solid Tumors
Article in Cancer Research Communications (April 2024)
The most recent citing publications are shown below. View all 120 publications that cite this research output on Dimensions.
Article in Cancer Research Communications (April 2024)
Article in Frontiers in Endocrinology (January 2024)
Article in Cytokine (January 2024)